Research Article


DOI :10.26650/IstanbulJPharm.2019.18005   IUP :10.26650/IstanbulJPharm.2019.18005    Full Text (PDF)

PPARγ Pro12Ala and C161T polymorphisms, but not PPARα L162V, are associated with osteoporosis risk in Turkish postmenopausal women

Özlem Kurt ŞirinHülya Yılmaz AydoğanMehmet UyarAyşe Can

Stimulation of peroxisome proliferator-activated receptors (PPARs) causes mesenchymal stem cells of the human bone marrow differentiate into adipocytes instead of osteoblasts leading to a decreased number of osteoblasts and a decrease in bone mineral density (BMD). Thus, PPARs may have impacts on bone metabolism. 224 postmenopausal women (171 osteoporotic and osteopenic, 53 healthy control) were included in this study. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and agarose gel electrophoresis techniques were performed to detect PPARα L162V and PPARγ Pro12Ala/C161T polymorphisms. The distribution of PPARγ Pro12Ala genotype and allele frequencies was not statistically different in control and patient (osteopenic+osteoporotic) groups (p>0.05). However, in the patient group, subjects with “Pro12Pro” genotype had lower lumbar spine (L1-L4) BMD values than those with “Ala” allele (p<0.05). The frequency of PPARγ C161T “CC” genotype was higher in the patient group when compared with that in the control group (p<0.05). There were no significant associations between the genotype and allele frequencies of PPARγ C161T/ PPARα L162V and BMD values (p>0.05). We suggested that PPARγ Pro12Ala and C161T gene variants might be contributing factors in the development of osteoporosis. 


PDF View

References

  • Abbott BD (2009). Review of the expression of peroxisome proliferator-activated receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development. Reprod Toxicol 27: 246-257. google scholar
  • Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL (2005). Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146: 1226-1235. google scholar
  • Atug O, Tahan V, Eren F, Tiftikci A, Imeryuz N, Hamzaoglu HO, Tozun N (2008). Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPARgamma) gene in inflammatory bowel disease. J Gastrointestin Liver Dis 17: 433-437. google scholar
  • Canbay E, Kurnaz O, Canbay B, Bugra D, Cakmakoglu B, Bulut T, Yamaner S, Sokucu N, Buyukuncu Y, Yilmaz-Aydogan H (2012). PPAR-gamma Pro12Ala polymorphism and gastric cancer risk in a Turkish population. Asian Pac J Cancer Prev 13: 5875-5878. google scholar
  • Chen ES, Mazzotti DR, Furuya TK, Cendoroglo MS, Ramos LR, Araujo LQ, Burbano RR, Smith Mde A (2010). Association of PPARalpha gene polymorphisms and lipid serum levels in a Brazilian elderly population. Exp Mol Pathol 88: 197-201. google scholar
  • Chia PP, Fan SH, Say YH (2015). Screening of Peroxisome Proliferator-Activated Receptors (PPARs) α, γ and α Gene Polymorphisms for Obesity and Metabolic Syndrome Association in the Multi-Ethnic Malaysian Population. Ethn Dis 25: 383-390. google scholar
  • Cho MC, Lee K, Paik SG, Yoon DY (2008). Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders. PPAR Res 2008: 679137. google scholar
  • Do HQ, Nazih H, Luc G, Arveiler D, Ferrières J, Evans A, Amouyel P, Cambien F, Ducimetière P, Bard JM (2009). Influence of cholesteryl ester transfer protein, peroxisome proliferator-activated receptor α, apolipoprotein E, and apolipoprotein A-I polymorphisms on high-density lipoprotein cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I:A-II concentrations: the Prospective Epidemiological Study of Myocardial Infarction study. Metabolism 58: 283-289. google scholar
  • Dragojevič J, Ostanek B, Mencej-Bedrač S, Komadina R, Preželj J, Marc J (2011). PPARG gene promoter polymorphism is associated with non-traumatic hip fracture risk in the elderly Slovenian population: a pilot study. Clin Biochem 44: 1085-1089. google scholar
  • Elrod HA, Sun SY (2008). PPARgamma and apoptosis in cancer. PPAR Res 2008: 704165. google scholar
  • Erdogan M, Karadeniz M, Eroglu Z, Tezcanli B, Selvi N, Yilmaz C (2007). The relationship of the peroxisome proliferator-activated receptor-gamma 2 exon 2 and exon 6 gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy. Diabetes Res Clin Pract 78: 355-359. google scholar
  • Fahmi H, Martel-Pelletier J, Pelletier JP, Kapoor M (2011). Peroxisome proliferator-activated receptor gamma in osteoarthritis. Mod Rheumatol 21: 1-9. google scholar
  • Flavell DM, Jamshidi Y, Hawe E, Torra IP, Taskinen MR, Frick MH, Nieminen MS, Kesäniemi YA, Pasternack A, Staels B, Miller G, Humphries SE, Talmud PJ, Miller G (2002). Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 105: 1440-1445. google scholar
  • Francès F, Verdú F, Portolés O, Castelló A, Sorlí JV, Guillen M, Corella D (2008). PPAR-alpha L162V and PGC-1 G482S gene polymorphisms, but not PPAR-gamma P12A, are associated with alcohol consumption in a Spanish Mediterranean population. Clin Chim Acta 398: 70-74. google scholar
  • Harsløf T, Tofteng CL, Husted LB, Nyegaard M, Børglum A, Carstens M, Stenkjær L, Brixen K, Eiken P, Jensen JE, Mosekilde L, Rejnmark L, Langdahl BL (2011). Polymorphisms of the peroxisome proliferator-activated receptor γ (PPARγ) gene are associated with osteoporosis.Osteoporos Int 22: 2655-2666. google scholar
  • Herlin M, McGuigan FE, Luthman H, Åkesson K (2015). Polymorphisms in inflammation associated genes ALOX15 and IL-6 are associated with bone properties in young women and fracture in elderly. Bone 79: 105-109. google scholar
  • Kapoor M, Kojima F, Qian M, Yang L, Crofford LJ (2007a). Microsomal prostaglandin E synthase-1 deficiency is associated with elevated peroxisome proliferator-activated receptor gamma: regulation by prostaglandin E2 via the phosphatidylinositol 3-kinase and Akt pathway. J Biol Chem 282: 5356-5366. google scholar
  • Kapoor M, Kojima F, Yang L, Crofford LJ (2007b). Sequential induction of pro- and anti-inflammatory prostaglandins and peroxisome proliferators-activated receptor-gamma during normal wound healing: a time course study. Prostaglandins Leukot Essent Fatty Acids 76: 103-112. google scholar
  • Koytak ES, Mizrak D, Bektaş M, Verdi H, Ergül AA, Idilman R, Çınar K, Yurdaydın C, Ersöz S, Karayalçın K, Uzunalimoğlu Ö, Bozkaya H (2008). PPAR-alpha L162V polymorphism in human hepatocellular carcinoma. Turk J Gastroenterol 19: 245-249. google scholar
  • Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Lebel P, Dallongeville J, Deeb S, Auwerx J, Amouyel P (1998). A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. Hum Mol Genet 7: 435-440. google scholar
  • Miller SA, Dykes DD, Poleskey HS (1998). Simples salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215. google scholar
  • Nadalin S, Giacometti J, Buretić-Tomljanović A (2014). PPARα-L162V polymorphism is not associated with schizophrenia risk in a Croatian population. Prostaglandins Leukot Essent Fatty Acids 91: 221-225. google scholar
  • Namvaran F, Rahimi-Moghaddam P, Azarpira N (2011). Genotyping of peroxisome proliferator-activated receptor gamma (PPAR-γ) polymorphism (Pro12Ala) in Iranian population. J Res Med Sci 16: 291-296. google scholar
  • Ogawa S, Urano T, Hosoi T, Miyao M, Hoshino S, Fujita M, Shiraki M, Orimo H, Ouchi Y, Inoue S (1999). Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARgamma expression in osteoblasts. Biochem Biophys Res Commun 260: 122-126. google scholar
  • Rhee EJ, Oh KW, Lee WY, Kim SY, Oh ES, Baek KH, Kang MI, Kim SW (2005). The effects of C161-->T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women. Am J Obstet Gynecol 192: 1087-1093. google scholar
  • Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B (2004). Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145: 401-406. google scholar
  • Sahmani M, Gholami A, Azarkeivan A, Darabi M, Ahmadi MH, Sabet MS, Najafipour R (2013). Peroxisome proliferator-activated receptor-γ Pro12Ala polymorphism and risk of osteopenia in β-thalassemia major patients. Hemoglobin 37: 564-573. google scholar
  • Stunes AK, Westbroek I, Gustafsson BI, Fossmark R, Waarsing JH, Eriksen EF, Petzold C, Reseland JE, Syversen U (2011). The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats. BMC Endocr Disord 11: 11. google scholar
  • Szanto A, Nagy L (2008). The many faces of PPARgamma: anti-inflammatory by any means? Immunobiology 213: 789-803. google scholar
  • Takano H, Komuro I (2009). Peroxisome proliferator-activated receptor gamma and cardiovascular diseases. Circ J 73: 214-220. google scholar
  • Tamaki J, Iki M, Morita A, Ikeda Y, Sato Y, Kajita E, Kagamimori S, Kagawa Y, Yoneshima H. (2010). Peroxisome proliferator-activated receptor gamma polymorphism is related to peak bone mass: the JPOS study. Osteoporos Int 21: 321-329. google scholar
  • Temelkova-Kurktschiev T, Hanefeld M, Chinetti G, Zawadzki C, Haulon S, Kubaszek A, Koehler C, Leonhardt W, Staels B, Laakso M (2004). Ala12Ala genotype of the peroxisome proliferator–activated receptor gamma2 protects against atherosclerosis. J Clin Endocrinol Metab 89: 4238-4242. google scholar
  • Touyz RM, Schiffrin EL (2006). Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.Vascul Pharmacol 45: 19-28. google scholar
  • Wang XL, Oosterhof J, Duarte N (1999). Peroxisome proliferator-activated receptor gamma C161→T polymorphism and coronary artery disease.Cardiovasc Res 44: 588-594. google scholar
  • Wang Y, Sugita N, Yoshihara A, Iwasaki M, Miyazaki H, Nakamura K, Yoshie H (2013). Peroxisome proliferator‐activated receptor (PPAR) γ polymorphism, vitamin D, bone mineral density and periodontitis in postmenopausal women. Oral Dis 19: 501-506. google scholar
  • World Health Organization Study Group (1994). Assesment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ Tech Rep Ser 843: 1-129. google scholar
  • Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, Burns DK, Roth J, Shuldiner AR (1997). Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 241: 270-274. google scholar
  • Yilmaz-Aydogan H, Kurnaz O, Kucukhuseyin O, Akadam-Teker B, Kurt O, Eronat AP, Tekeli A, Bugra Z, Ozturk O (2013). Different effects of PPARA, PPARG and ApoE SNPs on serum lipids in patients with coronary heart disease based on the presence of diabetes. Gene 523: 20-26. google scholar
  • Yilmaz-Aydogan H, Kurnaz O, Kurt O, Akadam-Teker B, Kucukhuseyin O, Tekeli A, Isbir T (2011). Effects of the PPARG P12A and C161T gene variants on serum lipids in coronary heart disease patients with and without Type 2 diabetes. Mol Cell Biochem 358: 355-363. google scholar
  • Yue H, He JW, Zhang H, Hu WW, Hu YQ, Li M, Liu YJ, Wu SH, Zhang ZL (2010). No association between polymorphisms of peroxisome [corrected] proliferator-activated receptor-gamma gene and peak bone mineral density variation in Chinese nuclear families. Osteoporos Int 21: 873-882. google scholar
  • Zhang ZF, Yang N, Zhao G, Zhu L, Wang LX (2012). Association between the Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma 2 and inflammatory bowel disease: a meta-analysis. PLoS One 7: e30551. google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Kurt Şirin, Ö., Yılmaz Aydoğan, H., Uyar, M., & Can, A. (2019). PPARγ Pro12Ala and C161T polymorphisms, but not PPARα L162V, are associated with osteoporosis risk in Turkish postmenopausal women. İstanbul Journal of Pharmacy, 49(1), 14-19. https://doi.org/10.26650/IstanbulJPharm.2019.18005


AMA

Kurt Şirin Ö, Yılmaz Aydoğan H, Uyar M, Can A. PPARγ Pro12Ala and C161T polymorphisms, but not PPARα L162V, are associated with osteoporosis risk in Turkish postmenopausal women. İstanbul Journal of Pharmacy. 2019;49(1):14-19. https://doi.org/10.26650/IstanbulJPharm.2019.18005


ABNT

Kurt Şirin, Ö.; Yılmaz Aydoğan, H.; Uyar, M.; Can, A. PPARγ Pro12Ala and C161T polymorphisms, but not PPARα L162V, are associated with osteoporosis risk in Turkish postmenopausal women. İstanbul Journal of Pharmacy, [Publisher Location], v. 49, n. 1, p. 14-19, 2019.


Chicago: Author-Date Style

Kurt Şirin, Özlem, and Hülya Yılmaz Aydoğan and Mehmet Uyar and Ayşe Can. 2019. “PPARγ Pro12Ala and C161T polymorphisms, but not PPARα L162V, are associated with osteoporosis risk in Turkish postmenopausal women.” İstanbul Journal of Pharmacy 49, no. 1: 14-19. https://doi.org/10.26650/IstanbulJPharm.2019.18005


Chicago: Humanities Style

Kurt Şirin, Özlem, and Hülya Yılmaz Aydoğan and Mehmet Uyar and Ayşe Can. PPARγ Pro12Ala and C161T polymorphisms, but not PPARα L162V, are associated with osteoporosis risk in Turkish postmenopausal women.” İstanbul Journal of Pharmacy 49, no. 1 (Jun. 2025): 14-19. https://doi.org/10.26650/IstanbulJPharm.2019.18005


Harvard: Australian Style

Kurt Şirin, Ö & Yılmaz Aydoğan, H & Uyar, M & Can, A 2019, 'PPARγ Pro12Ala and C161T polymorphisms, but not PPARα L162V, are associated with osteoporosis risk in Turkish postmenopausal women', İstanbul Journal of Pharmacy, vol. 49, no. 1, pp. 14-19, viewed 26 Jun. 2025, https://doi.org/10.26650/IstanbulJPharm.2019.18005


Harvard: Author-Date Style

Kurt Şirin, Ö. and Yılmaz Aydoğan, H. and Uyar, M. and Can, A. (2019) ‘PPARγ Pro12Ala and C161T polymorphisms, but not PPARα L162V, are associated with osteoporosis risk in Turkish postmenopausal women’, İstanbul Journal of Pharmacy, 49(1), pp. 14-19. https://doi.org/10.26650/IstanbulJPharm.2019.18005 (26 Jun. 2025).


MLA

Kurt Şirin, Özlem, and Hülya Yılmaz Aydoğan and Mehmet Uyar and Ayşe Can. PPARγ Pro12Ala and C161T polymorphisms, but not PPARα L162V, are associated with osteoporosis risk in Turkish postmenopausal women.” İstanbul Journal of Pharmacy, vol. 49, no. 1, 2019, pp. 14-19. [Database Container], https://doi.org/10.26650/IstanbulJPharm.2019.18005


Vancouver

Kurt Şirin Ö, Yılmaz Aydoğan H, Uyar M, Can A. PPARγ Pro12Ala and C161T polymorphisms, but not PPARα L162V, are associated with osteoporosis risk in Turkish postmenopausal women. İstanbul Journal of Pharmacy [Internet]. 26 Jun. 2025 [cited 26 Jun. 2025];49(1):14-19. Available from: https://doi.org/10.26650/IstanbulJPharm.2019.18005 doi: 10.26650/IstanbulJPharm.2019.18005


ISNAD

Kurt Şirin, Özlem - Yılmaz Aydoğan, Hülya - Uyar, Mehmet - Can, Ayşe. PPARγ Pro12Ala and C161T polymorphisms, but not PPARα L162V, are associated with osteoporosis risk in Turkish postmenopausal women”. İstanbul Journal of Pharmacy 49/1 (Jun. 2025): 14-19. https://doi.org/10.26650/IstanbulJPharm.2019.18005



TIMELINE


Accepted06.12.2018

LICENCE


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


SHARE



Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.